nodes	percent_of_prediction	percent_of_DWPC	metapath
Canagliflozin—UGT1A9—Mycophenolic acid—psoriasis	0.187	0.237	CbGbCtD
Canagliflozin—UGT1A9—Mycophenolate mofetil—psoriasis	0.104	0.132	CbGbCtD
Canagliflozin—ALB—Acitretin—psoriasis	0.0691	0.0876	CbGbCtD
Canagliflozin—ABCC2—Mycophenolate mofetil—psoriasis	0.0519	0.0658	CbGbCtD
Canagliflozin—ABCC2—Cyclosporine—psoriasis	0.0394	0.0499	CbGbCtD
Canagliflozin—ALB—Mycophenolate mofetil—psoriasis	0.0324	0.041	CbGbCtD
Canagliflozin—ABCC2—Dexamethasone—psoriasis	0.0259	0.0328	CbGbCtD
Canagliflozin—ALB—Prednisone—psoriasis	0.0259	0.0328	CbGbCtD
Canagliflozin—CYP3A4—Calcitriol—psoriasis	0.0227	0.0288	CbGbCtD
Canagliflozin—ABCC2—Methotrexate—psoriasis	0.0208	0.0264	CbGbCtD
Canagliflozin—CYP3A4—Methoxsalen—psoriasis	0.0177	0.0224	CbGbCtD
Canagliflozin—ABCB1—Mycophenolate mofetil—psoriasis	0.0169	0.0215	CbGbCtD
Canagliflozin—ABCB1—Betamethasone—psoriasis	0.0145	0.0184	CbGbCtD
Canagliflozin—ABCB1—Prednisolone—psoriasis	0.0143	0.0182	CbGbCtD
Canagliflozin—ABCB1—Hydrocortisone—psoriasis	0.0136	0.0172	CbGbCtD
Canagliflozin—ABCB1—Prednisone—psoriasis	0.0135	0.0172	CbGbCtD
Canagliflozin—ALB—Methotrexate—psoriasis	0.013	0.0164	CbGbCtD
Canagliflozin—ABCB1—Cyclosporine—psoriasis	0.0128	0.0163	CbGbCtD
Canagliflozin—CYP3A4—Cholecalciferol—psoriasis	0.0117	0.0148	CbGbCtD
Canagliflozin—CYP3A4—Mycophenolate mofetil—psoriasis	0.0101	0.0129	CbGbCtD
Canagliflozin—CYP3A4—Triamcinolone—psoriasis	0.0101	0.0129	CbGbCtD
Canagliflozin—CYP3A4—Betamethasone—psoriasis	0.0087	0.011	CbGbCtD
Canagliflozin—CYP3A4—Prednisolone—psoriasis	0.00859	0.0109	CbGbCtD
Canagliflozin—ABCB1—Dexamethasone—psoriasis	0.00845	0.0107	CbGbCtD
Canagliflozin—CYP3A4—Hydrocortisone—psoriasis	0.00814	0.0103	CbGbCtD
Canagliflozin—CYP3A4—Prednisone—psoriasis	0.00811	0.0103	CbGbCtD
Canagliflozin—CYP3A4—Cyclosporine—psoriasis	0.00769	0.00974	CbGbCtD
Canagliflozin—ABCB1—Methotrexate—psoriasis	0.00679	0.0086	CbGbCtD
Canagliflozin—CYP3A4—Dexamethasone—psoriasis	0.00506	0.00642	CbGbCtD
Canagliflozin—SLC5A1—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—CP—psoriasis	0.000385	0.0411	CbGpPWpGaD
Canagliflozin—SLC5A2—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—CP—psoriasis	0.000385	0.0411	CbGpPWpGaD
Canagliflozin—UGT2B4—Biological oxidations—CYP2S1—psoriasis	0.000367	0.0392	CbGpPWpGaD
Canagliflozin—UGT2B4—Metapathway biotransformation—CYP2S1—psoriasis	0.000362	0.0387	CbGpPWpGaD
Canagliflozin—SLC5A1—Orphan transporters—CARM1—psoriasis	0.000347	0.0371	CbGpPWpGaD
Canagliflozin—SLC5A2—Orphan transporters—CARM1—psoriasis	0.000347	0.0371	CbGpPWpGaD
Canagliflozin—Nausea—Methoxsalen—psoriasis	0.000288	0.00143	CcSEcCtD
Canagliflozin—Bladder pain—Methotrexate—psoriasis	0.000287	0.00142	CcSEcCtD
Canagliflozin—Urine output increased—Methotrexate—psoriasis	0.000287	0.00142	CcSEcCtD
Canagliflozin—Urinary tract disorder—Cyclosporine—psoriasis	0.000285	0.00141	CcSEcCtD
Canagliflozin—Hypersensitivity—Acitretin—psoriasis	0.000284	0.00141	CcSEcCtD
Canagliflozin—Hypersensitivity—Fluocinolone Acetonide—psoriasis	0.000283	0.0014	CcSEcCtD
Canagliflozin—Urethral disorder—Cyclosporine—psoriasis	0.000283	0.0014	CcSEcCtD
Canagliflozin—ABCB1—Allograft Rejection—IL22—psoriasis	0.00028	0.0299	CbGpPWpGaD
Canagliflozin—Syncope—Mycophenolic acid—psoriasis	0.000278	0.00138	CcSEcCtD
Canagliflozin—Urinary tract disorder—Mycophenolate mofetil—psoriasis	0.000278	0.00138	CcSEcCtD
Canagliflozin—Asthenia—Acitretin—psoriasis	0.000276	0.00137	CcSEcCtD
Canagliflozin—Urethral disorder—Mycophenolate mofetil—psoriasis	0.000276	0.00137	CcSEcCtD
Canagliflozin—Rash—Calcitriol—psoriasis	0.000273	0.00136	CcSEcCtD
Canagliflozin—Loss of consciousness—Mycophenolic acid—psoriasis	0.000273	0.00135	CcSEcCtD
Canagliflozin—Dermatitis—Calcitriol—psoriasis	0.000273	0.00135	CcSEcCtD
Canagliflozin—Pruritus—Acitretin—psoriasis	0.000272	0.00135	CcSEcCtD
Canagliflozin—Pruritus—Fluocinolone Acetonide—psoriasis	0.000272	0.00135	CcSEcCtD
Canagliflozin—Convulsion—Mycophenolic acid—psoriasis	0.000269	0.00133	CcSEcCtD
Canagliflozin—Diabetes mellitus—Methotrexate—psoriasis	0.000265	0.00131	CcSEcCtD
Canagliflozin—SLC5A1—NRF2 pathway—TGFA—psoriasis	0.000265	0.0283	CbGpPWpGaD
Canagliflozin—SLC5A2—NRF2 pathway—TGFA—psoriasis	0.000265	0.0283	CbGpPWpGaD
Canagliflozin—Unspecified disorder of skin and subcutaneous tissue—Mycophenolic acid—psoriasis	0.000262	0.0013	CcSEcCtD
Canagliflozin—Polyuria—Methotrexate—psoriasis	0.000262	0.0013	CcSEcCtD
Canagliflozin—Photosensitivity—Methotrexate—psoriasis	0.000262	0.0013	CcSEcCtD
Canagliflozin—Angiopathy—Cyclosporine—psoriasis	0.000262	0.0013	CcSEcCtD
Canagliflozin—Gastrointestinal disorder—Hydroxyurea—psoriasis	0.000261	0.0013	CcSEcCtD
Canagliflozin—Fatigue—Hydroxyurea—psoriasis	0.000261	0.00129	CcSEcCtD
Canagliflozin—Constipation—Hydroxyurea—psoriasis	0.000259	0.00128	CcSEcCtD
Canagliflozin—Dry mouth—Mycophenolic acid—psoriasis	0.000258	0.00128	CcSEcCtD
Canagliflozin—Nausea—Calcitriol—psoriasis	0.000257	0.00128	CcSEcCtD
Canagliflozin—Angiopathy—Mycophenolate mofetil—psoriasis	0.000255	0.00127	CcSEcCtD
Canagliflozin—Dizziness—Acitretin—psoriasis	0.000255	0.00126	CcSEcCtD
Canagliflozin—Dizziness—Fluocinolone Acetonide—psoriasis	0.000254	0.00126	CcSEcCtD
Canagliflozin—Infection—Mycophenolic acid—psoriasis	0.000252	0.00125	CcSEcCtD
Canagliflozin—Malnutrition—Cyclosporine—psoriasis	0.000251	0.00125	CcSEcCtD
Canagliflozin—Renal failure acute—Methotrexate—psoriasis	0.000249	0.00124	CcSEcCtD
Canagliflozin—Shock—Mycophenolic acid—psoriasis	0.000249	0.00124	CcSEcCtD
Canagliflozin—Nervous system disorder—Mycophenolic acid—psoriasis	0.000248	0.00123	CcSEcCtD
Canagliflozin—ABCC2—Drug Induction of Bile Acid Pathway—VDR—psoriasis	0.000246	0.0263	CbGpPWpGaD
Canagliflozin—Skin disorder—Mycophenolic acid—psoriasis	0.000246	0.00122	CcSEcCtD
Canagliflozin—Malnutrition—Mycophenolate mofetil—psoriasis	0.000245	0.00122	CcSEcCtD
Canagliflozin—Rash—Acitretin—psoriasis	0.000243	0.00121	CcSEcCtD
Canagliflozin—Dermatitis—Acitretin—psoriasis	0.000243	0.0012	CcSEcCtD
Canagliflozin—Rash—Fluocinolone Acetonide—psoriasis	0.000242	0.0012	CcSEcCtD
Canagliflozin—Dermatitis—Fluocinolone Acetonide—psoriasis	0.000242	0.0012	CcSEcCtD
Canagliflozin—Hypotension—Mycophenolic acid—psoriasis	0.000237	0.00117	CcSEcCtD
Canagliflozin—Pancreatitis—Prednisone—psoriasis	0.000234	0.00116	CcSEcCtD
Canagliflozin—Angioedema—Cyclosporine—psoriasis	0.000229	0.00114	CcSEcCtD
Canagliflozin—Nausea—Acitretin—psoriasis	0.000229	0.00114	CcSEcCtD
Canagliflozin—Erythema—Prednisolone—psoriasis	0.000228	0.00113	CcSEcCtD
Canagliflozin—Nausea—Fluocinolone Acetonide—psoriasis	0.000228	0.00113	CcSEcCtD
Canagliflozin—Angioedema—Mycophenolate mofetil—psoriasis	0.000224	0.00111	CcSEcCtD
Canagliflozin—Erythema—Hydrocortisone—psoriasis	0.000223	0.00111	CcSEcCtD
Canagliflozin—Malnutrition—Hydrocortisone—psoriasis	0.000223	0.00111	CcSEcCtD
Canagliflozin—Hypersensitivity—Hydroxyurea—psoriasis	0.000223	0.00111	CcSEcCtD
Canagliflozin—Syncope—Mycophenolate mofetil—psoriasis	0.00022	0.00109	CcSEcCtD
Canagliflozin—Gastrointestinal disorder—Mycophenolic acid—psoriasis	0.000219	0.00109	CcSEcCtD
Canagliflozin—Fatigue—Mycophenolic acid—psoriasis	0.000218	0.00108	CcSEcCtD
Canagliflozin—Convulsion—Cyclosporine—psoriasis	0.000217	0.00108	CcSEcCtD
Canagliflozin—Asthenia—Hydroxyurea—psoriasis	0.000217	0.00108	CcSEcCtD
Canagliflozin—Constipation—Mycophenolic acid—psoriasis	0.000217	0.00108	CcSEcCtD
Canagliflozin—Loss of consciousness—Mycophenolate mofetil—psoriasis	0.000215	0.00107	CcSEcCtD
Canagliflozin—CYP3A4—Xenobiotics—CYP2S1—psoriasis	0.000215	0.0229	CbGpPWpGaD
Canagliflozin—Unspecified disorder of skin and subcutaneous tissue—Cyclosporine—psoriasis	0.000212	0.00105	CcSEcCtD
Canagliflozin—Convulsion—Mycophenolate mofetil—psoriasis	0.000212	0.00105	CcSEcCtD
Canagliflozin—Erythema—Triamcinolone—psoriasis	0.00021	0.00104	CcSEcCtD
Canagliflozin—Dry mouth—Cyclosporine—psoriasis	0.000209	0.00104	CcSEcCtD
Canagliflozin—Angioedema—Prednisolone—psoriasis	0.000209	0.00104	CcSEcCtD
Canagliflozin—Breast disorder—Methotrexate—psoriasis	0.000208	0.00103	CcSEcCtD
Canagliflozin—Gastrointestinal pain—Mycophenolic acid—psoriasis	0.000207	0.00103	CcSEcCtD
Canagliflozin—Unspecified disorder of skin and subcutaneous tissue—Mycophenolate mofetil—psoriasis	0.000207	0.00103	CcSEcCtD
Canagliflozin—Syncope—Prednisolone—psoriasis	0.000205	0.00102	CcSEcCtD
Canagliflozin—Dry mouth—Mycophenolate mofetil—psoriasis	0.000204	0.00101	CcSEcCtD
Canagliflozin—Angioedema—Hydrocortisone—psoriasis	0.000204	0.00101	CcSEcCtD
Canagliflozin—Infection—Cyclosporine—psoriasis	0.000203	0.00101	CcSEcCtD
Canagliflozin—Nervous system disorder—Cyclosporine—psoriasis	0.000201	0.000997	CcSEcCtD
Canagliflozin—Loss of consciousness—Prednisolone—psoriasis	0.000201	0.000997	CcSEcCtD
Canagliflozin—Abdominal pain—Mycophenolic acid—psoriasis	0.0002	0.000994	CcSEcCtD
Canagliflozin—Syncope—Hydrocortisone—psoriasis	0.0002	0.000993	CcSEcCtD
Canagliflozin—Dizziness—Hydroxyurea—psoriasis	0.0002	0.000993	CcSEcCtD
Canagliflozin—Skin disorder—Cyclosporine—psoriasis	0.000199	0.000988	CcSEcCtD
Canagliflozin—Angiopathy—Dexamethasone—psoriasis	0.000199	0.000986	CcSEcCtD
Canagliflozin—Angiopathy—Betamethasone—psoriasis	0.000199	0.000986	CcSEcCtD
Canagliflozin—Infection—Mycophenolate mofetil—psoriasis	0.000199	0.000986	CcSEcCtD
Canagliflozin—Convulsion—Prednisolone—psoriasis	0.000198	0.000983	CcSEcCtD
Canagliflozin—Shock—Mycophenolate mofetil—psoriasis	0.000197	0.000976	CcSEcCtD
Canagliflozin—Loss of consciousness—Hydrocortisone—psoriasis	0.000196	0.000973	CcSEcCtD
Canagliflozin—Nervous system disorder—Mycophenolate mofetil—psoriasis	0.000196	0.000973	CcSEcCtD
Canagliflozin—Pancreatitis—Methotrexate—psoriasis	0.000195	0.000969	CcSEcCtD
Canagliflozin—Skin disorder—Mycophenolate mofetil—psoriasis	0.000194	0.000964	CcSEcCtD
Canagliflozin—Convulsion—Hydrocortisone—psoriasis	0.000193	0.00096	CcSEcCtD
Canagliflozin—Angioedema—Triamcinolone—psoriasis	0.000192	0.000953	CcSEcCtD
Canagliflozin—Rash—Hydroxyurea—psoriasis	0.000191	0.000946	CcSEcCtD
Canagliflozin—Erythema—Dexamethasone—psoriasis	0.000191	0.000946	CcSEcCtD
Canagliflozin—Erythema—Betamethasone—psoriasis	0.000191	0.000946	CcSEcCtD
Canagliflozin—Dermatitis—Hydroxyurea—psoriasis	0.00019	0.000946	CcSEcCtD
Canagliflozin—Unspecified disorder of skin and subcutaneous tissue—Hydrocortisone—psoriasis	0.000189	0.000936	CcSEcCtD
Canagliflozin—Syncope—Triamcinolone—psoriasis	0.000188	0.000935	CcSEcCtD
Canagliflozin—Hypotension—Mycophenolate mofetil—psoriasis	0.000187	0.000927	CcSEcCtD
Canagliflozin—Loss of consciousness—Triamcinolone—psoriasis	0.000185	0.000917	CcSEcCtD
Canagliflozin—Shock—Prednisolone—psoriasis	0.000183	0.000911	CcSEcCtD
Canagliflozin—Convulsion—Triamcinolone—psoriasis	0.000182	0.000904	CcSEcCtD
Canagliflozin—Photosensitivity reaction—Methotrexate—psoriasis	0.000182	0.000902	CcSEcCtD
Canagliflozin—Asthenia—Mycophenolic acid—psoriasis	0.000182	0.000902	CcSEcCtD
Canagliflozin—Infection—Hydrocortisone—psoriasis	0.000181	0.000898	CcSEcCtD
Canagliflozin—Nausea—Hydroxyurea—psoriasis	0.00018	0.000892	CcSEcCtD
Canagliflozin—Pruritus—Mycophenolic acid—psoriasis	0.000179	0.000889	CcSEcCtD
Canagliflozin—Shock—Hydrocortisone—psoriasis	0.000179	0.000889	CcSEcCtD
Canagliflozin—Nervous system disorder—Hydrocortisone—psoriasis	0.000179	0.000886	CcSEcCtD
Canagliflozin—Gastrointestinal disorder—Cyclosporine—psoriasis	0.000177	0.000878	CcSEcCtD
Canagliflozin—Skin disorder—Hydrocortisone—psoriasis	0.000177	0.000878	CcSEcCtD
Canagliflozin—Fatigue—Cyclosporine—psoriasis	0.000177	0.000877	CcSEcCtD
Canagliflozin—Constipation—Cyclosporine—psoriasis	0.000175	0.00087	CcSEcCtD
Canagliflozin—SLC5A2—SLC-mediated transmembrane transport—CP—psoriasis	0.000175	0.0187	CbGpPWpGaD
Canagliflozin—SLC5A1—SLC-mediated transmembrane transport—CP—psoriasis	0.000175	0.0187	CbGpPWpGaD
Canagliflozin—Dry mouth—Triamcinolone—psoriasis	0.000175	0.000868	CcSEcCtD
Canagliflozin—Angioedema—Dexamethasone—psoriasis	0.000174	0.000865	CcSEcCtD
Canagliflozin—Angioedema—Betamethasone—psoriasis	0.000174	0.000865	CcSEcCtD
Canagliflozin—Angiopathy—Prednisone—psoriasis	0.000173	0.000859	CcSEcCtD
Canagliflozin—Gastrointestinal disorder—Mycophenolate mofetil—psoriasis	0.000173	0.000857	CcSEcCtD
Canagliflozin—Syncope—Dexamethasone—psoriasis	0.000171	0.000849	CcSEcCtD
Canagliflozin—Syncope—Betamethasone—psoriasis	0.000171	0.000849	CcSEcCtD
Canagliflozin—Constipation—Mycophenolate mofetil—psoriasis	0.000171	0.000848	CcSEcCtD
Canagliflozin—Infection—Triamcinolone—psoriasis	0.00017	0.000846	CcSEcCtD
Canagliflozin—Hypotension—Hydrocortisone—psoriasis	0.00017	0.000845	CcSEcCtD
Canagliflozin—Shock—Triamcinolone—psoriasis	0.000169	0.000837	CcSEcCtD
Canagliflozin—Gastrointestinal pain—Cyclosporine—psoriasis	0.000167	0.000832	CcSEcCtD
Canagliflozin—Loss of consciousness—Dexamethasone—psoriasis	0.000167	0.000832	CcSEcCtD
Canagliflozin—Loss of consciousness—Betamethasone—psoriasis	0.000167	0.000832	CcSEcCtD
Canagliflozin—Dizziness—Mycophenolic acid—psoriasis	0.000167	0.000831	CcSEcCtD
Canagliflozin—Erythema—Prednisone—psoriasis	0.000166	0.000824	CcSEcCtD
Canagliflozin—Malnutrition—Prednisone—psoriasis	0.000166	0.000824	CcSEcCtD
Canagliflozin—Convulsion—Betamethasone—psoriasis	0.000165	0.00082	CcSEcCtD
Canagliflozin—Convulsion—Dexamethasone—psoriasis	0.000165	0.00082	CcSEcCtD
Canagliflozin—Gastrointestinal pain—Mycophenolate mofetil—psoriasis	0.000163	0.000811	CcSEcCtD
Canagliflozin—Urticaria—Cyclosporine—psoriasis	0.000163	0.000808	CcSEcCtD
Canagliflozin—Abdominal pain—Cyclosporine—psoriasis	0.000162	0.000804	CcSEcCtD
Canagliflozin—Rash—Mycophenolic acid—psoriasis	0.00016	0.000793	CcSEcCtD
Canagliflozin—Dermatitis—Mycophenolic acid—psoriasis	0.000159	0.000792	CcSEcCtD
Canagliflozin—Urticaria—Mycophenolate mofetil—psoriasis	0.000159	0.000788	CcSEcCtD
Canagliflozin—Abdominal pain—Mycophenolate mofetil—psoriasis	0.000158	0.000784	CcSEcCtD
Canagliflozin—Urinary tract disorder—Methotrexate—psoriasis	0.000157	0.000781	CcSEcCtD
Canagliflozin—Gastrointestinal disorder—Hydrocortisone—psoriasis	0.000157	0.00078	CcSEcCtD
Canagliflozin—Fatigue—Hydrocortisone—psoriasis	0.000157	0.000779	CcSEcCtD
Canagliflozin—Urethral disorder—Methotrexate—psoriasis	0.000156	0.000776	CcSEcCtD
Canagliflozin—Infection—Dexamethasone—psoriasis	0.000155	0.000767	CcSEcCtD
Canagliflozin—Infection—Betamethasone—psoriasis	0.000155	0.000767	CcSEcCtD
Canagliflozin—Shock—Dexamethasone—psoriasis	0.000153	0.00076	CcSEcCtD
Canagliflozin—Shock—Betamethasone—psoriasis	0.000153	0.00076	CcSEcCtD
Canagliflozin—Nervous system disorder—Dexamethasone—psoriasis	0.000153	0.000757	CcSEcCtD
Canagliflozin—Nervous system disorder—Betamethasone—psoriasis	0.000153	0.000757	CcSEcCtD
Canagliflozin—Angioedema—Prednisone—psoriasis	0.000152	0.000753	CcSEcCtD
Canagliflozin—UGT1A9—Aryl Hydrocarbon Receptor Pathway—IL12B—psoriasis	0.000151	0.0162	CbGpPWpGaD
Canagliflozin—Hypersensitivity—Cyclosporine—psoriasis	0.000151	0.000749	CcSEcCtD
Canagliflozin—Nausea—Mycophenolic acid—psoriasis	0.00015	0.000747	CcSEcCtD
Canagliflozin—Gastrointestinal pain—Hydrocortisone—psoriasis	0.000149	0.000739	CcSEcCtD
Canagliflozin—Syncope—Prednisone—psoriasis	0.000149	0.000739	CcSEcCtD
Canagliflozin—Urticaria—Prednisolone—psoriasis	0.000148	0.000735	CcSEcCtD
Canagliflozin—Fatigue—Triamcinolone—psoriasis	0.000148	0.000734	CcSEcCtD
Canagliflozin—Hypersensitivity—Mycophenolate mofetil—psoriasis	0.000147	0.000731	CcSEcCtD
Canagliflozin—Asthenia—Cyclosporine—psoriasis	0.000147	0.00073	CcSEcCtD
Canagliflozin—Loss of consciousness—Prednisone—psoriasis	0.000146	0.000724	CcSEcCtD
Canagliflozin—Hypotension—Betamethasone—psoriasis	0.000145	0.000722	CcSEcCtD
Canagliflozin—Hypotension—Dexamethasone—psoriasis	0.000145	0.000722	CcSEcCtD
Canagliflozin—Pruritus—Cyclosporine—psoriasis	0.000145	0.00072	CcSEcCtD
Canagliflozin—Urticaria—Hydrocortisone—psoriasis	0.000145	0.000718	CcSEcCtD
Canagliflozin—Angiopathy—Methotrexate—psoriasis	0.000145	0.000718	CcSEcCtD
Canagliflozin—Abdominal pain—Hydrocortisone—psoriasis	0.000144	0.000715	CcSEcCtD
Canagliflozin—Convulsion—Prednisone—psoriasis	0.000144	0.000714	CcSEcCtD
Canagliflozin—Asthenia—Mycophenolate mofetil—psoriasis	0.000143	0.000712	CcSEcCtD
Canagliflozin—ABCC2—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	0.000141	0.0151	CbGpPWpGaD
Canagliflozin—Pruritus—Mycophenolate mofetil—psoriasis	0.000141	0.000702	CcSEcCtD
Canagliflozin—Unspecified disorder of skin and subcutaneous tissue—Prednisone—psoriasis	0.00014	0.000697	CcSEcCtD
Canagliflozin—Malnutrition—Methotrexate—psoriasis	0.000139	0.000689	CcSEcCtD
Canagliflozin—Erythema—Methotrexate—psoriasis	0.000139	0.000689	CcSEcCtD
Canagliflozin—Hypersensitivity—Prednisolone—psoriasis	0.000137	0.000682	CcSEcCtD
Canagliflozin—Urticaria—Triamcinolone—psoriasis	0.000136	0.000676	CcSEcCtD
Canagliflozin—UGT1A9—Biological oxidations—CYP2S1—psoriasis	0.000136	0.0145	CbGpPWpGaD
Canagliflozin—Dizziness—Cyclosporine—psoriasis	0.000135	0.000673	CcSEcCtD
Canagliflozin—Infection—Prednisone—psoriasis	0.000135	0.000668	CcSEcCtD
Canagliflozin—Gastrointestinal disorder—Dexamethasone—psoriasis	0.000134	0.000667	CcSEcCtD
Canagliflozin—Gastrointestinal disorder—Betamethasone—psoriasis	0.000134	0.000667	CcSEcCtD
Canagliflozin—Hypersensitivity—Hydrocortisone—psoriasis	0.000134	0.000666	CcSEcCtD
Canagliflozin—Fatigue—Dexamethasone—psoriasis	0.000134	0.000666	CcSEcCtD
Canagliflozin—Fatigue—Betamethasone—psoriasis	0.000134	0.000666	CcSEcCtD
Canagliflozin—UGT1A9—Metapathway biotransformation—CYP2S1—psoriasis	0.000134	0.0143	CbGpPWpGaD
Canagliflozin—Shock—Prednisone—psoriasis	0.000133	0.000662	CcSEcCtD
Canagliflozin—Nervous system disorder—Prednisone—psoriasis	0.000133	0.00066	CcSEcCtD
Canagliflozin—Dizziness—Mycophenolate mofetil—psoriasis	0.000132	0.000656	CcSEcCtD
Canagliflozin—Skin disorder—Prednisone—psoriasis	0.000132	0.000653	CcSEcCtD
Canagliflozin—Asthenia—Hydrocortisone—psoriasis	0.000131	0.000649	CcSEcCtD
Canagliflozin—Rash—Cyclosporine—psoriasis	0.000129	0.000641	CcSEcCtD
Canagliflozin—Dermatitis—Cyclosporine—psoriasis	0.000129	0.000641	CcSEcCtD
Canagliflozin—Pruritus—Hydrocortisone—psoriasis	0.000129	0.00064	CcSEcCtD
Canagliflozin—Gastrointestinal pain—Betamethasone—psoriasis	0.000127	0.000631	CcSEcCtD
Canagliflozin—Gastrointestinal pain—Dexamethasone—psoriasis	0.000127	0.000631	CcSEcCtD
Canagliflozin—Hypersensitivity—Triamcinolone—psoriasis	0.000126	0.000627	CcSEcCtD
Canagliflozin—Rash—Mycophenolate mofetil—psoriasis	0.000126	0.000626	CcSEcCtD
Canagliflozin—Dermatitis—Mycophenolate mofetil—psoriasis	0.000126	0.000625	CcSEcCtD
Canagliflozin—Urticaria—Dexamethasone—psoriasis	0.000124	0.000613	CcSEcCtD
Canagliflozin—Urticaria—Betamethasone—psoriasis	0.000124	0.000613	CcSEcCtD
Canagliflozin—Dizziness—Prednisolone—psoriasis	0.000123	0.000612	CcSEcCtD
Canagliflozin—Asthenia—Triamcinolone—psoriasis	0.000123	0.000611	CcSEcCtD
Canagliflozin—Abdominal pain—Dexamethasone—psoriasis	0.000123	0.00061	CcSEcCtD
Canagliflozin—Abdominal pain—Betamethasone—psoriasis	0.000123	0.00061	CcSEcCtD
Canagliflozin—Nausea—Cyclosporine—psoriasis	0.000122	0.000604	CcSEcCtD
Canagliflozin—Pruritus—Triamcinolone—psoriasis	0.000121	0.000602	CcSEcCtD
Canagliflozin—Dizziness—Hydrocortisone—psoriasis	0.00012	0.000598	CcSEcCtD
Canagliflozin—Convulsion—Methotrexate—psoriasis	0.00012	0.000597	CcSEcCtD
Canagliflozin—Nausea—Mycophenolate mofetil—psoriasis	0.000119	0.000589	CcSEcCtD
Canagliflozin—Rash—Prednisolone—psoriasis	0.000118	0.000584	CcSEcCtD
Canagliflozin—Dermatitis—Prednisolone—psoriasis	0.000117	0.000583	CcSEcCtD
Canagliflozin—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—psoriasis	0.000117	0.000582	CcSEcCtD
Canagliflozin—ALB—HDL-mediated lipid transport—APOE—psoriasis	0.000117	0.0125	CbGpPWpGaD
Canagliflozin—Fatigue—Prednisone—psoriasis	0.000117	0.00058	CcSEcCtD
Canagliflozin—Constipation—Prednisone—psoriasis	0.000116	0.000575	CcSEcCtD
Canagliflozin—ABCB1—Drug Induction of Bile Acid Pathway—VDR—psoriasis	0.000116	0.0124	CbGpPWpGaD
Canagliflozin—Rash—Hydrocortisone—psoriasis	0.000115	0.00057	CcSEcCtD
Canagliflozin—Dermatitis—Hydrocortisone—psoriasis	0.000115	0.000569	CcSEcCtD
Canagliflozin—Dizziness—Triamcinolone—psoriasis	0.000113	0.000563	CcSEcCtD
Canagliflozin—Infection—Methotrexate—psoriasis	0.000112	0.000558	CcSEcCtD
Canagliflozin—Asthenia—Dexamethasone—psoriasis	0.000112	0.000554	CcSEcCtD
Canagliflozin—Asthenia—Betamethasone—psoriasis	0.000112	0.000554	CcSEcCtD
Canagliflozin—Nervous system disorder—Methotrexate—psoriasis	0.000111	0.000551	CcSEcCtD
Canagliflozin—Gastrointestinal pain—Prednisone—psoriasis	0.000111	0.00055	CcSEcCtD
Canagliflozin—Nausea—Prednisolone—psoriasis	0.000111	0.00055	CcSEcCtD
Canagliflozin—Pruritus—Dexamethasone—psoriasis	0.00011	0.000546	CcSEcCtD
Canagliflozin—Pruritus—Betamethasone—psoriasis	0.00011	0.000546	CcSEcCtD
Canagliflozin—Skin disorder—Methotrexate—psoriasis	0.00011	0.000546	CcSEcCtD
Canagliflozin—Nausea—Hydrocortisone—psoriasis	0.000108	0.000537	CcSEcCtD
Canagliflozin—Rash—Triamcinolone—psoriasis	0.000108	0.000537	CcSEcCtD
Canagliflozin—Dermatitis—Triamcinolone—psoriasis	0.000108	0.000536	CcSEcCtD
Canagliflozin—Urticaria—Prednisone—psoriasis	0.000108	0.000534	CcSEcCtD
Canagliflozin—Abdominal pain—Prednisone—psoriasis	0.000107	0.000532	CcSEcCtD
Canagliflozin—Hypotension—Methotrexate—psoriasis	0.000106	0.000525	CcSEcCtD
Canagliflozin—Dizziness—Betamethasone—psoriasis	0.000103	0.000511	CcSEcCtD
Canagliflozin—Dizziness—Dexamethasone—psoriasis	0.000103	0.000511	CcSEcCtD
Canagliflozin—Nausea—Triamcinolone—psoriasis	0.000102	0.000506	CcSEcCtD
Canagliflozin—Hypersensitivity—Prednisone—psoriasis	9.98e-05	0.000495	CcSEcCtD
Canagliflozin—ABCC2—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	9.86e-05	0.0105	CbGpPWpGaD
Canagliflozin—Rash—Betamethasone—psoriasis	9.81e-05	0.000487	CcSEcCtD
Canagliflozin—Rash—Dexamethasone—psoriasis	9.81e-05	0.000487	CcSEcCtD
Canagliflozin—Dermatitis—Dexamethasone—psoriasis	9.8e-05	0.000486	CcSEcCtD
Canagliflozin—Dermatitis—Betamethasone—psoriasis	9.8e-05	0.000486	CcSEcCtD
Canagliflozin—Gastrointestinal disorder—Methotrexate—psoriasis	9.77e-05	0.000485	CcSEcCtD
Canagliflozin—Fatigue—Methotrexate—psoriasis	9.76e-05	0.000485	CcSEcCtD
Canagliflozin—Asthenia—Prednisone—psoriasis	9.72e-05	0.000483	CcSEcCtD
Canagliflozin—Pruritus—Prednisone—psoriasis	9.58e-05	0.000476	CcSEcCtD
Canagliflozin—SLC5A2—Metabolism—NDUFA5—psoriasis	9.56e-05	0.0102	CbGpPWpGaD
Canagliflozin—SLC5A1—Metabolism—NDUFA5—psoriasis	9.56e-05	0.0102	CbGpPWpGaD
Canagliflozin—UGT1A9—PPARA activates gene expression—CARM1—psoriasis	9.49e-05	0.0101	CbGpPWpGaD
Canagliflozin—UGT1A9—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—CARM1—psoriasis	9.29e-05	0.00992	CbGpPWpGaD
Canagliflozin—Gastrointestinal pain—Methotrexate—psoriasis	9.26e-05	0.00046	CcSEcCtD
Canagliflozin—Nausea—Betamethasone—psoriasis	9.24e-05	0.000459	CcSEcCtD
Canagliflozin—Nausea—Dexamethasone—psoriasis	9.24e-05	0.000459	CcSEcCtD
Canagliflozin—Urticaria—Methotrexate—psoriasis	8.99e-05	0.000447	CcSEcCtD
Canagliflozin—Dizziness—Prednisone—psoriasis	8.96e-05	0.000445	CcSEcCtD
Canagliflozin—Abdominal pain—Methotrexate—psoriasis	8.95e-05	0.000444	CcSEcCtD
Canagliflozin—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	8.92e-05	0.00953	CbGpPWpGaD
Canagliflozin—SLC5A1—Transmembrane transport of small molecules—CP—psoriasis	8.89e-05	0.0095	CbGpPWpGaD
Canagliflozin—SLC5A2—Transmembrane transport of small molecules—CP—psoriasis	8.89e-05	0.0095	CbGpPWpGaD
Canagliflozin—CYP3A4—Oxidation by Cytochrome P450—CYP2S1—psoriasis	8.8e-05	0.0094	CbGpPWpGaD
Canagliflozin—Rash—Prednisone—psoriasis	8.54e-05	0.000424	CcSEcCtD
Canagliflozin—Dermatitis—Prednisone—psoriasis	8.53e-05	0.000424	CcSEcCtD
Canagliflozin—SLC5A2—Transmembrane transport of small molecules—CARM1—psoriasis	8.48e-05	0.00906	CbGpPWpGaD
Canagliflozin—SLC5A1—Transmembrane transport of small molecules—CARM1—psoriasis	8.48e-05	0.00906	CbGpPWpGaD
Canagliflozin—Hypersensitivity—Methotrexate—psoriasis	8.34e-05	0.000414	CcSEcCtD
Canagliflozin—SLC5A1—Metabolism—CYP2S1—psoriasis	8.13e-05	0.00869	CbGpPWpGaD
Canagliflozin—SLC5A2—Metabolism—CYP2S1—psoriasis	8.13e-05	0.00869	CbGpPWpGaD
Canagliflozin—Asthenia—Methotrexate—psoriasis	8.12e-05	0.000403	CcSEcCtD
Canagliflozin—Nausea—Prednisone—psoriasis	8.05e-05	0.000399	CcSEcCtD
Canagliflozin—Pruritus—Methotrexate—psoriasis	8.01e-05	0.000398	CcSEcCtD
Canagliflozin—UGT1A9—NRF2 pathway—TGFA—psoriasis	7.56e-05	0.00808	CbGpPWpGaD
Canagliflozin—Dizziness—Methotrexate—psoriasis	7.49e-05	0.000372	CcSEcCtD
Canagliflozin—UGT2B4—Metabolism—NDUFA5—psoriasis	7.38e-05	0.00789	CbGpPWpGaD
Canagliflozin—ABCC2—NRF2 pathway—TGFA—psoriasis	7.38e-05	0.00789	CbGpPWpGaD
Canagliflozin—CYP3A4—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	7.23e-05	0.00772	CbGpPWpGaD
Canagliflozin—Rash—Methotrexate—psoriasis	7.14e-05	0.000354	CcSEcCtD
Canagliflozin—CYP3A4—Drug Induction of Bile Acid Pathway—VDR—psoriasis	7.13e-05	0.00762	CbGpPWpGaD
Canagliflozin—Dermatitis—Methotrexate—psoriasis	7.13e-05	0.000354	CcSEcCtD
Canagliflozin—ABCB1—HIF-1-alpha transcription factor network—CP—psoriasis	6.87e-05	0.00734	CbGpPWpGaD
Canagliflozin—Nausea—Methotrexate—psoriasis	6.72e-05	0.000334	CcSEcCtD
Canagliflozin—ALB—Lipoprotein metabolism—APOE—psoriasis	6.71e-05	0.00717	CbGpPWpGaD
Canagliflozin—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	6.65e-05	0.0071	CbGpPWpGaD
Canagliflozin—UGT1A9—Aryl Hydrocarbon Receptor Pathway—IFNG—psoriasis	6.51e-05	0.00696	CbGpPWpGaD
Canagliflozin—UGT1A9—Fatty acid, triacylglycerol, and ketone body metabolism—CARM1—psoriasis	6.4e-05	0.00684	CbGpPWpGaD
Canagliflozin—UGT2B4—Metabolism—CYP2S1—psoriasis	6.28e-05	0.00671	CbGpPWpGaD
Canagliflozin—UGT1A9—Aryl Hydrocarbon Receptor Pathway—JUN—psoriasis	5.63e-05	0.00601	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—SERPINB8—psoriasis	5.48e-05	0.00585	CbGpPWpGaD
Canagliflozin—ABCB1—Allograft Rejection—HLA-C—psoriasis	5.3e-05	0.00566	CbGpPWpGaD
Canagliflozin—ABCB1—Allograft Rejection—IL13—psoriasis	5.27e-05	0.00563	CbGpPWpGaD
Canagliflozin—ALB—Binding and Uptake of Ligands by Scavenger Receptors—APOE—psoriasis	5.23e-05	0.00559	CbGpPWpGaD
Canagliflozin—ABCB1—Allograft Rejection—IL17A—psoriasis	4.85e-05	0.00518	CbGpPWpGaD
Canagliflozin—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	4.63e-05	0.00495	CbGpPWpGaD
Canagliflozin—ALB—Folate Metabolism—CAT—psoriasis	4.6e-05	0.00491	CbGpPWpGaD
Canagliflozin—ABCB1—Allograft Rejection—IL12B—psoriasis	4.51e-05	0.00481	CbGpPWpGaD
Canagliflozin—ALB—Vitamin B12 Metabolism—CRP—psoriasis	4.49e-05	0.00479	CbGpPWpGaD
Canagliflozin—ALB—Lipid and lipoprotein metabolism—APOE—psoriasis	4.46e-05	0.00477	CbGpPWpGaD
Canagliflozin—ABCB1—Allograft Rejection—HLA-E—psoriasis	4.4e-05	0.0047	CbGpPWpGaD
Canagliflozin—ALB—Vitamin B12 Metabolism—APOE—psoriasis	4.39e-05	0.00469	CbGpPWpGaD
Canagliflozin—ALB—Folate Metabolism—IL4—psoriasis	4.22e-05	0.00451	CbGpPWpGaD
Canagliflozin—UGT1A9—Aryl Hydrocarbon Receptor Pathway—TNF—psoriasis	4.21e-05	0.0045	CbGpPWpGaD
Canagliflozin—ALB—Vitamin B12 Metabolism—ICAM1—psoriasis	4.12e-05	0.00441	CbGpPWpGaD
Canagliflozin—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	4.1e-05	0.00438	CbGpPWpGaD
Canagliflozin—SLC5A1—Metabolism—CARM1—psoriasis	3.97e-05	0.00424	CbGpPWpGaD
Canagliflozin—SLC5A2—Metabolism—CARM1—psoriasis	3.97e-05	0.00424	CbGpPWpGaD
Canagliflozin—UGT1A9—PPARA activates gene expression—PPARG—psoriasis	3.95e-05	0.00422	CbGpPWpGaD
Canagliflozin—UGT1A9—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—PPARG—psoriasis	3.87e-05	0.00413	CbGpPWpGaD
Canagliflozin—CYP3A4—Biological oxidations—CYP2S1—psoriasis	3.84e-05	0.0041	CbGpPWpGaD
Canagliflozin—CYP3A4—Metapathway biotransformation—CYP2S1—psoriasis	3.79e-05	0.00405	CbGpPWpGaD
Canagliflozin—ALB—Selenium Micronutrient Network—CAT—psoriasis	3.65e-05	0.0039	CbGpPWpGaD
Canagliflozin—ALB—Folate Metabolism—CRP—psoriasis	3.65e-05	0.0039	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—PTTG1—psoriasis	3.64e-05	0.00389	CbGpPWpGaD
Canagliflozin—ALB—Folate Metabolism—ICAM1—psoriasis	3.36e-05	0.00359	CbGpPWpGaD
Canagliflozin—CYP3A4—Tryptophan metabolism—CAT—psoriasis	3.31e-05	0.00354	CbGpPWpGaD
Canagliflozin—ABCB1—Allograft Rejection—IL10—psoriasis	3.29e-05	0.00352	CbGpPWpGaD
Canagliflozin—ABCB1—Allograft Rejection—IL4—psoriasis	3.2e-05	0.00342	CbGpPWpGaD
Canagliflozin—ALB—Vitamin B12 Metabolism—IFNG—psoriasis	3.14e-05	0.00335	CbGpPWpGaD
Canagliflozin—ABCB1—Allograft Rejection—HLA-B—psoriasis	3.13e-05	0.00335	CbGpPWpGaD
Canagliflozin—ABCB1—HIF-1-alpha transcription factor network—LEP—psoriasis	3.13e-05	0.00334	CbGpPWpGaD
Canagliflozin—UGT2B4—Metabolism—CARM1—psoriasis	3.07e-05	0.00328	CbGpPWpGaD
Canagliflozin—ABCB1—HIF-1-alpha transcription factor network—NOS2—psoriasis	2.92e-05	0.00312	CbGpPWpGaD
Canagliflozin—ABCB1—Allograft Rejection—HLA-A—psoriasis	2.9e-05	0.0031	CbGpPWpGaD
Canagliflozin—ALB—Selenium Micronutrient Network—CRP—psoriasis	2.9e-05	0.0031	CbGpPWpGaD
Canagliflozin—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	2.86e-05	0.00305	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—NDUFA5—psoriasis	2.73e-05	0.00292	CbGpPWpGaD
Canagliflozin—ALB—Selenium Micronutrient Network—ICAM1—psoriasis	2.67e-05	0.00285	CbGpPWpGaD
Canagliflozin—UGT1A9—Fatty acid, triacylglycerol, and ketone body metabolism—PPARG—psoriasis	2.66e-05	0.00285	CbGpPWpGaD
Canagliflozin—ABCB1—Allograft Rejection—HLA-DRB1—psoriasis	2.65e-05	0.00283	CbGpPWpGaD
Canagliflozin—ALB—SLC-mediated transmembrane transport—CP—psoriasis	2.62e-05	0.0028	CbGpPWpGaD
Canagliflozin—ALB—Vitamin B12 Metabolism—NFKB1—psoriasis	2.61e-05	0.00279	CbGpPWpGaD
Canagliflozin—ALB—Folate Metabolism—IFNG—psoriasis	2.55e-05	0.00273	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism of lipids and lipoproteins—CARM1—psoriasis	2.55e-05	0.00272	CbGpPWpGaD
Canagliflozin—ABCC2—Transmembrane transport of small molecules—CP—psoriasis	2.48e-05	0.00265	CbGpPWpGaD
Canagliflozin—SLC5A1—Metabolism—CAT—psoriasis	2.44e-05	0.00261	CbGpPWpGaD
Canagliflozin—SLC5A2—Metabolism—CAT—psoriasis	2.44e-05	0.00261	CbGpPWpGaD
Canagliflozin—SLC5A1—Disease—HLA-A—psoriasis	2.43e-05	0.00259	CbGpPWpGaD
Canagliflozin—SLC5A2—Disease—HLA-A—psoriasis	2.43e-05	0.00259	CbGpPWpGaD
Canagliflozin—ABCC2—Transmembrane transport of small molecules—CARM1—psoriasis	2.36e-05	0.00253	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—CYP2S1—psoriasis	2.32e-05	0.00248	CbGpPWpGaD
Canagliflozin—SLC5A2—Disease—APOE—psoriasis	2.27e-05	0.00242	CbGpPWpGaD
Canagliflozin—SLC5A1—Disease—APOE—psoriasis	2.27e-05	0.00242	CbGpPWpGaD
Canagliflozin—ALB—Folate Metabolism—NFKB1—psoriasis	2.12e-05	0.00227	CbGpPWpGaD
Canagliflozin—SLC5A1—Disease—NOS2—psoriasis	2.11e-05	0.00226	CbGpPWpGaD
Canagliflozin—SLC5A2—Disease—NOS2—psoriasis	2.11e-05	0.00226	CbGpPWpGaD
Canagliflozin—ALB—Vitamin B12 Metabolism—TNF—psoriasis	2.03e-05	0.00217	CbGpPWpGaD
Canagliflozin—ALB—Selenium Micronutrient Network—IFNG—psoriasis	2.03e-05	0.00217	CbGpPWpGaD
Canagliflozin—ABCB1—Allograft Rejection—IFNG—psoriasis	1.94e-05	0.00207	CbGpPWpGaD
Canagliflozin—ABCB1—HIF-1-alpha transcription factor network—JUN—psoriasis	1.93e-05	0.00207	CbGpPWpGaD
Canagliflozin—SLC5A2—Metabolism—APOE—psoriasis	1.9e-05	0.00203	CbGpPWpGaD
Canagliflozin—SLC5A1—Metabolism—APOE—psoriasis	1.9e-05	0.00203	CbGpPWpGaD
Canagliflozin—UGT2B4—Metabolism—CAT—psoriasis	1.89e-05	0.00202	CbGpPWpGaD
Canagliflozin—ABCB1—Allograft Rejection—CXCL8—psoriasis	1.8e-05	0.00192	CbGpPWpGaD
Canagliflozin—SLC5A1—Disease—TYK2—psoriasis	1.73e-05	0.00185	CbGpPWpGaD
Canagliflozin—SLC5A2—Disease—TYK2—psoriasis	1.73e-05	0.00185	CbGpPWpGaD
Canagliflozin—ABCB1—HIF-1-alpha transcription factor network—VEGFA—psoriasis	1.69e-05	0.00181	CbGpPWpGaD
Canagliflozin—ALB—Selenium Micronutrient Network—NFKB1—psoriasis	1.69e-05	0.0018	CbGpPWpGaD
Canagliflozin—ALB—Platelet degranulation—VEGFA—psoriasis	1.65e-05	0.00177	CbGpPWpGaD
Canagliflozin—SLC5A1—Metabolism—PPARG—psoriasis	1.65e-05	0.00177	CbGpPWpGaD
Canagliflozin—SLC5A2—Metabolism—PPARG—psoriasis	1.65e-05	0.00177	CbGpPWpGaD
Canagliflozin—ALB—Folate Metabolism—TNF—psoriasis	1.65e-05	0.00177	CbGpPWpGaD
Canagliflozin—ALB—Vitamin B12 Metabolism—IL6—psoriasis	1.64e-05	0.00175	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—ITGAL—psoriasis	1.59e-05	0.0017	CbGpPWpGaD
Canagliflozin—ALB—Response to elevated platelet cytosolic Ca2+—VEGFA—psoriasis	1.57e-05	0.00168	CbGpPWpGaD
Canagliflozin—SLC5A2—Disease—CD4—psoriasis	1.56e-05	0.00167	CbGpPWpGaD
Canagliflozin—SLC5A1—Disease—CD4—psoriasis	1.56e-05	0.00167	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—PCNA—psoriasis	1.48e-05	0.00159	CbGpPWpGaD
Canagliflozin—UGT2B4—Metabolism—APOE—psoriasis	1.47e-05	0.00157	CbGpPWpGaD
Canagliflozin—ABCB1—Allograft Rejection—VEGFA—psoriasis	1.46e-05	0.00156	CbGpPWpGaD
Canagliflozin—ALB—Folate Metabolism—TP53—psoriasis	1.46e-05	0.00156	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—NDUFA5—psoriasis	1.43e-05	0.00153	CbGpPWpGaD
Canagliflozin—ALB—Metabolism of lipids and lipoproteins—CARM1—psoriasis	1.33e-05	0.00143	CbGpPWpGaD
Canagliflozin—ALB—Folate Metabolism—IL6—psoriasis	1.33e-05	0.00142	CbGpPWpGaD
Canagliflozin—ALB—Transmembrane transport of small molecules—CP—psoriasis	1.33e-05	0.00142	CbGpPWpGaD
Canagliflozin—ALB—Selenium Micronutrient Network—TNF—psoriasis	1.31e-05	0.0014	CbGpPWpGaD
Canagliflozin—UGT2B4—Metabolism—PPARG—psoriasis	1.28e-05	0.00136	CbGpPWpGaD
Canagliflozin—ALB—Transmembrane transport of small molecules—CARM1—psoriasis	1.27e-05	0.00136	CbGpPWpGaD
Canagliflozin—ABCB1—Allograft Rejection—TNF—psoriasis	1.25e-05	0.00134	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—NDUFA5—psoriasis	1.25e-05	0.00134	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—NFKBIA—psoriasis	1.25e-05	0.00133	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism of lipids and lipoproteins—APOE—psoriasis	1.22e-05	0.0013	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—CYP2S1—psoriasis	1.22e-05	0.0013	CbGpPWpGaD
Canagliflozin—SLC5A2—Disease—STAT3—psoriasis	1.21e-05	0.00129	CbGpPWpGaD
Canagliflozin—SLC5A1—Disease—STAT3—psoriasis	1.21e-05	0.00129	CbGpPWpGaD
Canagliflozin—ABCB1—Transmembrane transport of small molecules—CP—psoriasis	1.16e-05	0.00124	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—CARM1—psoriasis	1.13e-05	0.00121	CbGpPWpGaD
Canagliflozin—ABCB1—Transmembrane transport of small molecules—CARM1—psoriasis	1.11e-05	0.00119	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—CYP2S1—psoriasis	1.07e-05	0.00114	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism of lipids and lipoproteins—PPARG—psoriasis	1.06e-05	0.00113	CbGpPWpGaD
Canagliflozin—ALB—Selenium Micronutrient Network—IL6—psoriasis	1.06e-05	0.00113	CbGpPWpGaD
Canagliflozin—SLC5A2—Disease—IL6—psoriasis	8.46e-06	0.000904	CbGpPWpGaD
Canagliflozin—SLC5A1—Disease—IL6—psoriasis	8.46e-06	0.000904	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—JUN—psoriasis	8.26e-06	0.000883	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—NFKB1—psoriasis	7.96e-06	0.00085	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—NDUFA5—psoriasis	7.72e-06	0.000825	CbGpPWpGaD
Canagliflozin—ALB—Platelet activation, signaling and aggregation—VEGFA—psoriasis	7.33e-06	0.000784	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—psoriasis	7.22e-06	0.000771	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—CAT—psoriasis	6.98e-06	0.000746	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—CYP2S1—psoriasis	6.57e-06	0.000702	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—NOS2—psoriasis	6.53e-06	0.000697	CbGpPWpGaD
Canagliflozin—ALB—Metabolism of lipids and lipoproteins—APOE—psoriasis	6.38e-06	0.000681	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—psoriasis	6.19e-06	0.000661	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—CARM1—psoriasis	5.94e-06	0.000635	CbGpPWpGaD
Canagliflozin—ALB—Metabolism of lipids and lipoproteins—PPARG—psoriasis	5.55e-06	0.000593	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—psoriasis	5.46e-06	0.000583	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—APOE—psoriasis	5.42e-06	0.000579	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—CARM1—psoriasis	5.21e-06	0.000556	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—PPARG—psoriasis	4.72e-06	0.000505	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—VEGFA—psoriasis	3.78e-06	0.000404	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—CAT—psoriasis	3.65e-06	0.00039	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—CARM1—psoriasis	3.21e-06	0.000343	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—CAT—psoriasis	3.2e-06	0.000342	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—TP53—psoriasis	2.86e-06	0.000305	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—APOE—psoriasis	2.84e-06	0.000303	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—APOE—psoriasis	2.49e-06	0.000266	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—PPARG—psoriasis	2.47e-06	0.000264	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—PPARG—psoriasis	2.17e-06	0.000232	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—CAT—psoriasis	1.97e-06	0.000211	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—APOE—psoriasis	1.53e-06	0.000164	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—PPARG—psoriasis	1.34e-06	0.000143	CbGpPWpGaD
